Answers are grounded in this paper and cite their sources.
Background Non–Down syndrome acute megakaryoblastic leukemia (non–DS–AMKL) is a rare but high-risk subtype of pediatric AML with dismal outcomes. Allo-HSCT in first complete remission (CR1) is recommended as the preferred strategy for improving survival, yet the benefit of BU/CY intensification with melphalan (MEL) or thiotepa (TT) remains unclear. Methods We retrospectively analyzed 70 pediatric non–DS–AMKL patients undergoing ATG/G-CSF–based haplo-HSCT between March 2010 and February 2024, comparing standard BU/CY (n=25) with intensified BU+MEL/TT (n=45). Endpoints included OS, LFS, RI, NRM, and TRM. Survival was estimated by Kaplan–Meier and compared with the log-rank test, while cumulative incidences were analyzed using Gray’s test. Cox proportional hazards and Fine–Gray competing-risk regression models were applied for univariate and multivariate analyses, as appropriate. Results Baseline clinical characteristics were comparable between groups, whereas graft CD34+ (median, 10.40×10 6 /kg vs 5.85×10 6 /kg) and CD3+ (median, 4.54×10 8 /kg vs 1.89×10 8 /kg) cell doses were significantly higher in the BU+MEL/TT group (both P<0.001). Median follow-up was 25 months (range, 13–91.2). Day-100 TRM was similar between groups (6.67% vs 8.00%, P = 0.81), with no significant differences in engraftment, GVHD, viral reactivations. No VOD/SOS or TMA events were observed. Among patients transplanted in CR, the BU+MEL/TT group demonstrated superior 5-year OS (75.2% vs 50.0%, P = 0.045) and LFS (76.3% vs 50.0%, P = 0.039), with numerically lower RI and NRM. In contrast, patients transplanted in NR/PR had poor outcomes in both groups, with 1-year OS and LFS of approximately 20%. In multivariable Cox analyses, intensified conditioning (BU+MEL/TT vs BU) improved OS (HR 0.20, P = 0.047) and LFS (HR 0.29, P = 0.034). Complex cytogenetics (OS: HR 2.38, P = 0.016; LFS: HR 2.58, P = 0.011) and pre-transplant NR/PR status (OS: HR 5.53, P = 0.001; LFS: HR 3.55, P = 0.004) were independent adverse factors. In competing-risk models, conditioning was not associated with RI or NRM, whereas NR/PR status significantly increased relapse (HR 3.39, P = 0.019) and NRM (HR 3.73, P = 0.007). Conclusions In pediatric non–DS–AMKL, intensified conditioning (BU+MEL/TT) independently improved OS and LFS in patients transplanted in CR without increasing early NRM. Pre-transplant NR/PR status was the strongest adverse factor, markedly increasing RI and NRM, underscoring the importance of achieving remission before transplantation.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: